Introduction
Chronic lymphocytic leukemia (CLL) remains one of the most commonly diagnosed lymphoid malignancies in Western countries. Historically, CLL has been considered as an indolent disease in which patients are placed under 'watchful waiting' until the disease progresses. 1, 2 Once therapy is deemed necessary, palliation has been the standard approach to treatment. This was largely due to the previous lack of effective therapies that could induce complete remission and due to the older age of patients (median 65-70 years at diagnosis) 3 with CLL; thus, patients were often thought to die of causes unrelated to their disease. Both the Binet and Rai 4, 5 staging systems for CLL have traditionally been used to stratify patients into prognostic groups based on assessments of disease burden. Although the staging systems play a critical role in determining the natural course of the disease and the need for therapy, they do not predict for the likelihood of disease progression among patients with early-stage (Rai stage 0 or Binet stage A) disease. Large clinical studies by the French Cooperative Group have demonstrated that even among patients with previously untreated Binet stage A disease, approximately 40% progressed to advanced stages and 45% ultimately required therapy. 6 In addition, more than 20% of patients eventually died of CLLrelated causes. Although CLL is often thought to affect elderly individuals, about 30% of patients with CLL are below 65 years of age and 12% are below 55 years. 3 Importantly, younger patients (o55 years) appear to have significantly higher risks of dying of CLL-related causes compared with older patients. 7 With CLL being diagnosed in younger patients and in earlier stages because of routine blood tests, and with the realization that a large proportion of patients with early-stage disease progress to a more advanced disease stage requiring therapy, additional prognostic parameters are needed to identify the subgroup of patients with early-stage disease who are at risk for disease progression, poorer response to therapy, and more importantly, shortened survival. In recent decades, various prognostic factors have been reported in CLL, which could potentially identify the subgroups of high-risk patients who are likely to have a more aggressive course of disease. The present review aims to summarize our current understanding of novel prognostic markers in CLL and provides recommendations on how high-risk subgroups of patients may be identified based on these newer prognostic markers.
Overview of prognostic markers in CLL
The 'traditional' prognostic markers in CLL include factors such as disease stage and lymphocyte doubling time (LDT). As noted earlier, the Rai and Binet staging systems have played a central role in evaluating prognosis in CLL; patients with early-stage disease (Rai 0 or Binet A) have an estimated median survival of 410 years, whereas those with intermediate-stage (Rai I/II or Binet B) and advanced-stage (Rai III/IV or Binet C) disease have a median survival of 5-7 years and o3 years, respectively. 4, 5 LDT is a measure of the kinetics of cellular proliferation and is based on the number of months it takes for the lymphocyte count to double. Although LDTo12 months has been shown to be predictive of poorer survival, 8, 9 determination of LDT is retrospective by nature, and its utility as a prognostic marker may be confounded by other factors that affect lymphocyte counts. 10 Moreover, factors such as disease stage and LDT (which partially correlates with disease stage) are reflective of disease burden rather than being predictive of disease progression. Various serum markers such as b 2 -microglobulin, 11 CD23 12,13 and thymidine kinase 11, 14 have also been shown to have prognostic implications in patients with CLL. In the past decade, several new biological markers have been identified as having prognostic relevance in CLL, including the mutational status of the variable region of the immunoglobulin heavy chain (IgV H ), CD38, z-chain-associated protein kinase (ZAP-70)) and genomic abnormalities. The major strength of these newer prognostic markers is their potential role in predictingFrather than being reflective ofFdisease progression and/or therapeutic outcomes in patients with low tumor burden.
IgV H mutation
The mutational status of IgV H identifies two subgroups of CLL patients with different prognoses and is predictive of survival outcomes in patients with CLL. Depending on the clinical situation, patients with mutated IgV H constitute about 30-60% of CLL cases and have favorable outcomes with a median survival of 10-20 years from time of diagnosis; conversely, patients with unmutated IgV H have significantly poorer outcomes, with a median survival of 5-10 years from diagnosis. 15À19 The negative prognostic impact of unmutated IgV H on survival was also found to be relevant among patients with early-stage (that is, Binet stage A) CLL. 16, 17 Unmutated IgV H has also been associated with decreased progression-free survival (PFS) among patients with early-stage, asymptomatic disease (from the CLL1 study of the German CLL Study Group (GCLLSG)) 19 (Bergmann et al., Blood 2003; 102: 665a, abstract 2464), further attesting to its potential significance in the biology of the disease. In addition, unmutated IgV H has been associated with decreased PFS and overall survival (OS) in patients treated with first-line fludarabine-based combination regimens. 20, 21 Further data from ongoing prospective studies are needed to confirm these findings, and new relevant data are emerging from several cooperative study groups (further discussed below). Unmutated IgV H status has been shown to be significantly predictive of minimal residual disease (MRD) positivity following autologous stem cell transplantation (SCT), which in turn correlated with eventual clinical relapse or disease progression. 22 This finding suggests that IgV H status remains an important prognostic marker in patients with CLL undergoing autologous SCT. Conversely, allogeneic SCT following reducedintensity conditioning has been shown to induce durable MRDnegative remissions even in patients with unmutated IgV H status, likely due to the graft-versus-leukemia effect afforded by allogeneic SCT. 23À26 Although it is clear that IgV H mutational status is an important prognostic marker in CLL, determination of the mutational status is labor-intensive and may not yet be practical in the routine clinical setting.
Potential associated markers for IgV H mutational status
Recent studies have reported on the prognostic relevance of several markers, such as CD38 and ZAP-70, which may serve as associated markers for IgV H mutational status. CD38 is a cellsurface antigen expressed on various hematopoietic and nonhematopoietic cells, including on B cells. In an earlier study by Damle et al., 15 high levels of CD38 expression (CD38 þ in X30% of CLL cells) were found to correlate significantly with unmutated IgV H , which was further confirmed by subsequent studies. 17, 27 Notably, CD38 þ predicted for both significantly shorter PFS (approximately 3 years from diagnosis) 28 and OS (approximately 8-10 years from diagnosis). 15, 17, 28 The association of decreased survival with CD38 þ also was apparent among patients with low to intermediate-risk ( þ was associated with decreased response and/or significantly shorter PFS in patients treated with first-line fludarabine-based therapy. 21, 27 The expression of CD38 can be readily assessed by flow cytometry methods and therefore may be a more accessible alternative to determining IgV H mutational status. However, limitations exist in incorporating CD38 as a surrogate marker for IgV H status: CD38 levels may change by more than 10% during the course of disease in a portion of patients, although this is only likely to alter the CD38 positivity status in very few patients (5% or less). 17, 27, 30 In addition, the relationship between CD38 and IgV H status has been reported to be discordant in up to a third of CLL cases.
17 CD38 expression is associated with other markers of cellular activation, including CD49d, CD18 and CD20. 31 CD49d is a cell-surface antigen that functions as part of a celladhesion molecule. High expression of CD49d predicts for decreased survival outcomes in patients with CLL, 32 and studies are ongoing to further evaluate the prognostic value of this marker and to determine the optimal cut-off levels for its expression.
ZAP-70 is an intracellular tyrosine kinase involved in the normal T-cell signaling pathway. This kinase can be expressed in CLL cells, but is typically not expressed in normal mature B cells. However, ZAP-70 has been detected in normal activated tonsillar and splenic B cells. 33 The plausibility of using ZAP-70 as a marker associated with IgV H mutational status stems from initial studies of gene expression profiling using DNA microarrays, which demonstrated that ZAP-70 expression could differentiate between the two IgV H subgroups (that is, elevated ZAP-70 expression (ZAP-70 þ ) associated with unmutated IgV H ). 34, 35 A pivotal study established the correlation between ZAP-70 (as determined by flow cytometry) and IgV H mutational status in addition to its prognostic relevance. 36 ZAP-70 was found to be highly predictive of IgV H mutational status (concordance rate 490%), with prognostic significance comparable to that of IgV H status: patients with ZAP-70 þ CLL had a median survival of 8-9 years from the time of diagnosis compared with 24 years among patients with ZAP-70 -CLL. 35, 37 Of note, recent studies in large patient cohorts have reported discordance in ZAP-70/IgV H status in more than 20% of CLL cases and have further suggested that patients with ZAP-70 þ may have worse outcomes regardless of IgV H mutational status. 27, 38, 39 Interestingly, studies have reported on the high frequency of VH3-21 gene usage among patients with discordant ZAP-70 þ /mutated IgV H , and frequent occurrence of 11q and 17p deletions -two genomic aberrations associated with adverse outcomes -among discordant cases with ZAP-70 -unmutated IgV H . 35, 38 Usage of the VH3-21 gene segment has been associated with progressive disease and short survival irrespective of IgV H mutation status. 40 Although ZAP-70 appears to be a powerful prognostic marker with potential use in lieu of, or in conjunction with, IgV H mutational status, the need for standardization of ZAP-70 assays is a significant impediment to its use in routine clinical settings. At this time, there is substantial variability in the techniques used for detecting or measuring ZAP-70, the types or condition of specimens used for analysis, and the reporting or interpretation of testing results. Therefore, until such standardized assays become available and validated in prospective studies, ZAP-70 alone may not be a reliable prognostic marker for making treatment decisions in individual patients. 41 Other markers, such as lipoprotein lipase (an enzyme involved in lipid metabolism) expression and telomere length, are currently under investigation for their potential role as surrogate markers for IgV H mutational status and their independent prognostic relevance in patients with CLL.
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Genomic aberrations
Genomic abnormalities detected by interphase cytogenetic assays such as fluorescence in situ hybridization (FISH) are emerging as an important prognostic indicator in CLL. In a large cohort of consecutive patients with CLL, Dohner et al. 44 identified genomic abnormalities in 82% of patients using FISH cytogenetic analysis. In this study, the investigators identified five genetic risk categories in a hierarchical model (that is, 17pÀ, 11qÀ, trisomy 12q, normal, 13qÀ as sole abnormality) that differed significantly in terms of disease progression and OS. In particular, deletions of 17p or 11q were highly predictive of decreased survival; patients with 17pÀ have the poorest outcomes with significantly shorter treatment-free interval (median 9 months from diagnosis) and OS (median 32 months from diagnosis) compared with other risk categories. 44 Deletion of 17p results in the loss of the tumor suppressor gene TP53, whereas deletion of 11q results in loss of the ATM gene, which activates p53 and is involved in the cell cycle checkpoint pathway. Deletions of TP53 or ATM are frequently, but not always, associated with an inactivating mutation of the remaining allele, potentially resulting in p53 dysfunction. 45, 46 The latter is readily detectable as impaired radiation-induced upregulation of p53 and one of its transcriptional targets, p21, 47, 48 and is associated with VH3-21 usage, 49 deletion of 17p and 11q, 50 and short survival. 51 Genomic abnormalities, including poor-prognosis aberrations such as 17pÀ and 11qÀ, are also present in early-stage, untreated patients with CLL and have been associated with decreased PFS even among those with asymptomatic disease. 19, 52 In addition, the 17pÀ and 11qÀ abnormalities appear to occur predominantly in patients with unmutated IgV H status. 18, 38, 53 Genomic aberrations detectable by FISH, including those known to be high-risk aberrations, may change over time during the course of disease in a given patient; one study has estimated that over a 5-year period, this may occur in 25% of patients with CLL. 54, 55 Abnormal structural rearrangements, such as translocations, are not visible by routine FISH assays unless specific translocations are predefined and included in the probe sets. Thus, novel methods using stimulated CLL cells are being incorporated to evaluate further these genomic abnormalities. In recent studies, translocations were reported in 20-40% of patients with CLL when stimulation protocols with CD40 ligand or CpG-oligodeoxynucleotides were employed. 56, 57 Patients with translocations had significantly decreased treatment-free survival (median 24 vs 106 months; Po0.001) and decreased OS (median 94 vs 346 months; Po0.001). Interestingly, all patients with 17pÀ had translocations, and the treatment-free survival was similar between patients with translocations without 17pÀ and patients with 17pÀ (median 24 vs 18 months). 57 Importantly, the presence of genomic abnormalities has been shown to affect treatment outcomes in patients with CLL. Early studies showed that p53 deletions or mutations predicted for non-response to therapy and shorter survival in patients treated with purine analogs or alkylating agents. 58, 59 Recent data from several independent studies further demonstrated that 17pÀ were significantly predictive of poorer response and shorter PFS and OS among patients with CLL treated with first-line fludarabine-based regimens 20 
Issues surrounding the definition of 'high-risk' CLL
The therapeutic landscape of CLL management has been undergoing dynamic changes in recent decades, and several elements argue in favor of a more risk-adapted approach to the treatment of CLL. First, there is increased detection of patients with early-stage CLL because of routine physical examinations and/or health-screening programs, and we now know that some patients with early-stage disease can experience an aggressive course of disease resulting in poorer survival outcome. Second, with the current availability of highly effective therapies as well as sensitive assays that can detect residual disease at very low levels, it is possible to induce deeper levels of remission that may translate into improved survival -although this has yet to be correlated with enhanced survivorship in prospective studies. Lastly, there is increasing awareness about new prognostic markers, both among clinicians and among patients with CLL.
Challenges and basic considerations in defining 'high risk'
In assessing the role of prognostic factors in identifying high-risk subgroups of patients with CLL, one must bear in mind that the ability of newer prognostic markers to predict outcomes is largely dependent on the clinical situation of each patient. Thus, a prognostic marker that may be useful in predicting disease progression in a patient with early stage, previously untreated CLL may not be as predictive for this end point in a patient with previously treated, relapsed and/or refractory disease. In addition, prognostic markers predict for different end points, such as disease progression, OS and/or resistance to therapy, and some markers may be predictive for several end points. To add to the complexity, prognostic markers may overlap and the significance of a marker may not always be independent of the presence of other markers; hence, the incorporation of multivariate regression analysis becomes important in clinical studies. Moreover, it is plausible that different prognostic markers may be combined to provide a more refined approach to risk stratification. Lastly, evaluation of several prognostic markers considered to be predictive for the same end point (for example, disease progression) may produce discordant results.
Multivariate analyses of prognostic factors
In a study from the MD Anderson Cancer Center that analyzed prognostic factors in large cohorts of treatment-naïve (n ¼ 659) and previously treated (n ¼ 1062) patients with CLL, b 2 -microglobulin was found to be a significant prognostic indicator for response to therapy, time to treatment failure and OS in both cohorts following multivariate regression analysis that included, among other covariates, disease stage, age and CD38 (Wierda et al., Blood 2005; 106: 336b, abstract 5018). However, the study analyzed data from patients enrolled in clinical studies dating from 1974 and therefore did not include, as covariates, some of the newer and potentially critical prognostic factors such as IgV H mutational status, ZAP-70 or genomic aberrations.
Recent studies employing multivariate analyses reveal the differential prognostic impacts of the newer prognostic markers depending on the covariates used. Both ZAP-70 and CD38 were significant, independent prognostic factors for PFS in a multivariate regression model that included the covariates age, modified Rai stage, b 2 -microglobulin and soluble CD23; however, for analyses of OS, only ZAP-70 remained a significant prognostic indicator. 27 In other studies, IgV H mutational status, but not CD38, remained significantly predictive of decreased survival in a multivariate regression model that included, among other covariates, presence of genomic abnormalities. 18, 53 In a recent multivariate regression analysis, two models were developed, both of which include high-risk genomic aberrations (that is, 17pÀ or 11qÀ) and, alternatively, IgV H mutation status and VH3-21 usage or ZAP-70 expression as independent outcome predictors. 38 In studies that analyzed disease stage, IgV H mutational status (98% cutoff) and genomic abnormalities in a multivariate regression model, the presence of 17pÀ or 11qÀ (or ATM mutation) remained a significant independent predictor for decreased survival, 18, 45, 53 further confirming the negative impact of these abnormalities in patients with CLL. In one of these studies, Krober et al. 18 further developed a risk model based on the results of multivariate regression analysis that evaluated the independent prognostic significance of IgV H mutational status, 17pÀ and 11qÀ. The model stratifies patients using four genetic risk subgroups including -in order of poorer to better survival outcomes -presence of 17pÀ (regardless of IgV H mutational status), presence of 11qÀ (no 17pÀ but regardless of IgV H mutational status), unmutated IgV H (no 17pÀ or 11qÀ) and mutated IgV H (no 17pÀ or 11qÀ) (Figure 1a) . The genetic risk categories used in this model were also applicable to patients with early-stage (Binet A) disease (Figure 1b Further studies are needed to assess comprehensively the prognostic impact of the newer markers (for example, unmutated IgV H , ZAP-70, CD38, genomic aberrations) relative to the more traditional markers such as disease stage, LDT, age and serum markers including b 2 -microglobulin. Studies are also needed to evaluate the overall risk profile of patients whose tests show discordant results for prognostic markers that are predictive of similar end points.
Assessment of high-risk CLL
Again, it is important to note that prognostic markers may have different predictive values in different clinical situations; moreover, the frequency of certain prognostic markers (for example, 17pÀ, unmutated IgV H ) may vary between patient subgroups depending on the stage of disease and status of earlier treatments. 19 Thus, high-risk features may need to be assessed within the context of these different clinical situations (Table 1) , including in patients with (1) early-stage, untreated disease, (2) progressive disease requiring therapy and (3) advanced-stage or fludarabine-refractory disease. Even among patients with early stage, previously untreated CLL, approximately 25-50% will have high-risk features, 61 including 17pÀ or 11qÀ (12-14% among Rai stage 0-2 or Binet A), 19, 54 unmutated IgV H (28-40% among Binet A) 17, 19 and/or ZAP-70 þ (52% among Rai 0 or Binet A). 36 The presence of 17pÀ alone can be considered a high-risk feature predictive of disease progression and/or potential resistance to alkylating agents and purine analogbased therapies, although the frequency of 17pÀ is much lower in patients with early stage or asymptomatic disease compared with patients in more advanced stages of CLL. It should be emphasized that the predictive implications of the markers summarized in Table 1 are mainly based on results from univariate analyses and data from retrospective studies outside of clinical trials. One exception is 17pÀ, which has consistently demonstrated its significance as a predictor for chemoresistance and shorter survival in multivariate analysis. As mentioned previously, only preliminary data are available from prospective clinical studies that evaluate the independent prognostic significance of all identified markers. It is still unclear whether these novel markers are most useful individually or in combination. All patients with advanced-stage or fludarabinerefractory disease may have poor prognosis regardless of the presence of other prognostic markers and therefore should be considered at high risk for rapid disease progression and projected decreased survival. In this patient subgroup, evaluation of unfavorable genomic abnormalities (that is, 17pÀ, 11qÀ or trisomy 12q) and b 2 -microglobulin levels may provide additional guidance for treatment decisions, because both factors have been shown to be significant predictors for shorter time to progression and decreased survival with fludarabine and cyclophosphamide (FC) therapy combined with rituximab (FCR regimen). 62 However, the main contribution of the newer prognostic markers to Rai or Binet staging is likely to be in adding a degree of risk stratification for the subgroup of patients who are destined to have clinical progression despite early-stage disease. Several ongoing clinical trials are prospectively evaluating the effect of prognostic markers on treatment outcomes. The CLL7 trial of the GCLLSG includes initial risk stratification among patients with Binet stage A disease using factors such as thymidine kinase, LDT, genomic aberrations and IgV H mutational status; high-risk patients will either be treated with FCR or be under 'watchful waiting' until disease progression, whereas low-risk patients will be under 'watchful waiting' only. In the international collaborative CLL8 trial of the GCLLSG, patients with Binet stage B or C disease will be randomized to receive therapy with FC or FCR to assess the role of rituximab. In parallel, biological risk markers such as IgV H mutational status, genomic aberrations, gene mutations and gene expression will be correlated to clinical outcomes. In the United Kingdom, analysis of prognostic factors within the Leukaemia Research Fund CLL4 trial has led to the definition of three risk groups for future clinical trials: high risk (17pÀ), intermediate risk (unmutated IgV H or VH3-21 usage) and low risk (none of these markers). The UKCLL206 and the German-French CLL2O trials are evaluating alemtuzumab in combination with high-dose corticosteroids in patients with high-risk CLL (17pÀ and/or fludarabine-refractory disease) based upon promising preliminary results. 63 Finally, the ECOG 2903 trial in the United States will evaluate the effect of genomic abnormalities on clinical outcomes in patients with relapsed and/or refractory CLL treated with pentostatin, cyclophosphamide and rituximab combination therapy followed by alemtuzumab consolidation.
Summary and conclusions
Emerging prognostic factors may be critical in differentiating patients who are likely to experience rapidly progressive CLL; thus, the predictive value of prognostic markers may be more important in patients with previously untreated, early-stage disease. Clinical studies are currently under way to evaluate the relative prognostic value of emerging and traditional markers, and to address optimal treatment approaches for the subgroups of patients with high-risk CLL. It is important to note that most of the new prognostic markers have been investigated either in small patient series or in retrospective analyses. Moreover, these markers often have not been tested in comparison with all other available parameters. Therefore, the use of these new prognostic markers as the basis for deciding when to initiate therapy or what therapy to administer appears premature, except in the context of prospective clinical trials designed to evaluate the value of these markers on treatment-related decisions. Until such evidence becomes available, the decision to initiate treatment should continue to be based on the criteria outlined in the 1996 National Cancer Institute-sponsored Working Group guidelines. 64, 65 Patients with advanced-stage or fludarabine-refractory disease should be considered high risk for disease progression and decreased survival regardless of other prognostic markers. The presence of 17pÀ alone may be considered high risk for rapid disease progression and decreased survival in all clinical situations. In the study of salvage FCR therapy, genomic abnormalities were categorized only as unfavorable (that is, 17pÀ, 11qÀ, trisomy 12 or complex) versus favorable (normal or 13qÀ as the sole abnormality); unfavorable genomic abnormalities were an independent predictor of decreased TTP and OS in the multivariate analysis. 62 
